Skip to content
TrialScanner

NCT04106557

A Study of OV101 in Individuals With Angelman Syndrome (AS)

Phase 3CompletedOVIDLead

Registry record

Lead sponsor
Ovid Therapeutics Inc.
Conditions
Primary Disease or Condition Being Studied: Angelman Syndrome (AS)
Primary completion
Nov 2, 2020Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04106557 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04106557: A Study of OV101 in Individua... | TrialScanner